Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intas bolsters European hospitals supplies base via Spanish deal

This article was originally published in Scrip

Executive Summary

Intas Pharmaceuticals of India has snapped up the hospitals business of Spain's Combino Pharm, bolstering its presence in the hospitals supplies segment in Europe.

You may also be interested in...



Intas Builds Europe Scale With £603m Teva Deal

Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.

Torrent On Course For Buy, US Momentum

Torrent Pharmaceuticals Ltd may have opted out of the race for the injectables firm Gland Pharma Ltd, but the Indian company stays interested in a buy to build its "hospital presence".

Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift

Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.

Topics

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel